GT Biopharma cuts shareholder quorum to one-third
GT Biopharma, Inc. amended its bylaws on June 8, 2026 to lower the shareholder meeting quorum requirement from a majority of outstanding voting shares to one-third of the outstanding shares entitled to vote.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
GT Biopharma, Inc. amended its bylaws on June 8, 2026 to lower the shareholder meeting quorum requirement from a majority of outstanding voting shares to one-third of the outstanding shares entitled to vote. This change is intended to make it easier to reach a quorum and hold shareholder meetings.
The Board cited a growing trend of brokerage firms not using discretionary or proportionate voting for street-name holdings, which has made majority quorums harder to achieve. The amendment is effective June 8, 2026 and is documented as Amendment No. 1 to the Amended and Restated Bylaws.
8-K Event Classification
2 items: 5.03, 9.01
2 items
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
New quorum threshold: one-third of outstanding shares
Prior quorum threshold: majority of outstanding shares
Amendment effective date: June 8, 2026
3 metrics
New quorum threshold
one-third of outstanding shares
Quorum for shareholder meetings effective June 8, 2026
Prior quorum threshold
majority of outstanding shares
Previous requirement for shareholder meeting quorum
Amendment effective date
June 8, 2026
Date Board approved Amendment No. 1 to bylaws
Key Terms
quorum, Amended and Restated Bylaws, street name, emerging growth company
4 terms
quorum financial
"to reduce the number of shares that are required to be present in person or by proxy at a meeting of the Company’s stockholders (a “Meeting”) for purposes of establishing a quorum."
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
Amended and Restated Bylaws regulatory
"approved an amendment (the “Amendment”) to the Company’s Amended and Restated Bylaws, effective June 8, 2026"
A company’s amended and restated bylaws are its internal rulebook rewritten to include all changes in one updated document, replacing the old bylaws. For investors, this matters because the bylaws set how the board, shareholders and officers make decisions, hold votes and handle disputes; a new consolidated version can change voting rights, control mechanisms or procedures that affect corporate governance and the value or risk of an investment.
street name financial
"brokerage firms opting to forgo discretionary or proportionate voting of the shares held by them in street name"
A "street name" is a way that stocks or other financial assets are registered under a broker's name rather than directly in an individual investor's name. This allows for easier buying, selling, and transferring of the assets, much like how a library might hold books on behalf of many readers. For investors, using a street name simplifies transactions and helps maintain privacy, but it also means the broker is the official record holder of ownership.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What governance change did GTBP disclose in its June 2026 8-K?
GT Biopharma disclosed a bylaw amendment lowering its shareholder meeting quorum requirement from a majority of outstanding voting shares to one-third. This change is meant to make it easier for the company to hold meetings and conduct business when shareholders are convened.
What was GTBP’s quorum requirement before the June 8, 2026 amendment?
Before the amendment, GT Biopharma required a majority of outstanding shares entitled to vote to be present in person or by proxy for a quorum. After the change, not less than one-third of outstanding voting shares is sufficient to conduct shareholder meeting business.
Why did GT Biopharma’s board reduce the quorum requirement to one-third?
The board reduced the quorum requirement because more brokerage firms are choosing not to cast discretionary or proportionate votes for street-name shares. This trend makes it harder to reach majority quorums, so a one-third threshold helps ensure meetings can proceed as planned.
When did GTBP’s new quorum requirement become effective?
GT Biopharma’s new quorum requirement became effective on June 8, 2026, the date the board approved Amendment No. 1 to its Amended and Restated Bylaws. From that date onward, one-third of outstanding voting shares constitutes a quorum for shareholder meetings.
Where can investors find the full text of GTBP’s bylaw amendment?
Investors can find the full text of the bylaw amendment in Exhibit 3.1, titled Amendment No. 1 to the Amended and Restated Bylaws of GT Biopharma, Inc. It is attached to the current report and incorporated in the disclosure by reference.
Does GT Biopharma still maintain a physical principal executive office?
Effective July 1, 2024, GT Biopharma became a fully remote company and does not maintain a traditional principal executive office. Shareholder communications can be directed to 505 Montgomery Street, 10th Floor, San Francisco, California 94111, or to auditcommittee@gtbiopharma.com.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates